Related Articles
Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers
PI3K inhibition sensitizes EGFR wild‑type NSCLC cell lines to erlotinib chemotherapy
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib
Continuous exposure of non‑small cell lung cancer cells with wild‑type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3
Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR‑TKI‑sensitive, primary resistant and acquired resistant human non‑small cell lung cancer cells